# Neoadjuvant Lazertinib Therapy in EGFR-Mutation Positive Lung Adenocarcinoma Detected by BALF Liquid Biopsy

Source: https://onco.cc/trials/nct05469022/  
OnCo record `nct05469022` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial in lung cancer, run by Konkuk University Medical Center, now recruiting.

## Summary

Neoadjuvant Lazertinib Therapy in EGFR-Mutation Positive Lung Adenocarcinoma Detected by BALF Liquid Biopsy is a phase 2, interventional study registered as NCT05469022 by Konkuk University Medical Center, with a registry enrolment figure of 40 participants, started 2022-05-19 and due to reach its primary completion in 2024-05-19. Interventions recorded: Neoadjuvant lazertinib. Conditions listed: Non Small Cell Lung Cancer. Primary outcome: Objective response rate. Lung eligibility wording from the registry: "Patients with suspected lung cancer on chest CT findings". Sites: South Korea. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-25
- Tags: ctgov-ingest; lung-deep-dive
- Registry id: NCT05469022
- Phase: 2
- Setting: A Phase II, Single-Center, Single-Arm, Prospective Study of Neoadjuvant Lazertinib Therapy in Resectable EGFR-Mutation Positive Lung Adenocarcinoma Patients Detected by Broncho-alveolar Lavage Fluid(BALF) Liquid Biopsy
- Sponsor: Konkuk University Medical Center
- Enrolled: 40

## Sources

- ClinicalTrials.gov NCT05469022: https://clinicaltrials.gov/study/NCT05469022

## Connected records

- cancers: [EGFR-mutated non-small-cell lung cancer](https://onco.cc/cancers/egfr-mutant-nsclc/), [Resectable stage I to III non-small-cell lung cancer](https://onco.cc/cancers/resectable-nsclc/)
- companies: [Yuhan Corporation](https://onco.cc/companies/yuhan/)
- terms: [Lung cancer trials open today (registry snapshot)](https://onco.cc/terms/lung-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct05469022.json